(S)-4-(1-(5-chloro-2-(4-fluorophenyoxy) benzamido)ethyl) benzoic acid

a selective antagonist of prostaglandin E receptor subtype 4; structure in second source

Also Known As:

(4-((1S)-1-((5-chloro-2-((4-fluorophenyl)oxy)phenyl)carbonyl)amino)ethyl)benzoic acid; CJ-042794; CJ-42794; RQ 00015986; RQ-00015986; RQ00015986

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Ulcer 10/01/2007 - "By contrast, CJ-42794 (selective EP(4) antagonist) significantly delayed the ulcer healing in rats and mice. "
2.	Stomach Ulcer (Gastric Ulcer) 09/01/2007 - "These results suggest that CJ-42794 does not cause any damage in the normal rat gastrointestinal mucosa and in the arthritic rat stomach and does not worsen the gastric ulcerogenic response to stress or aspirin in normal rats, although this agent slightly damages the small intestine of arthritic rats and impairs the healing of gastric ulcers." 09/01/2007 - "The repeated administration of CJ-42794 and rofecoxib as well as indomethacin impaired the healing of chronic gastric ulcers with a down-regulation of vascular endothelial growth factor expression in the ulcerated mucosa. "
3.	Neoplasms (Cancer) 01/01/2017 - "The potent and selective prostanoid EP4 receptor antagonist CJ-042794 was radiolabeled with 18F, and evaluated for imaging EP4 receptor expression in cancer with positron emission tomography (PET). " 01/01/2017 - "Synthesis and evaluation of 18F-labeled CJ-042794 for imaging prostanoid EP4 receptor expression in cancer with positron emission tomography."

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Prostaglandins
3.	Indomethacin (Indometacin)
4.	Aspirin (Acetylsalicylic Acid)
5.	rofecoxib (Vioxx)